No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
YMAB Y-mAbs Therapeutics
- 8.150
- +0.040+0.49%
Close Dec 24 13:00 ET
- 8.150
- 0.0000.00%
Post 13:01 ET
365.03MMarket Cap-15.09P/E (TTM)
8.225High7.800Low150.23KVolume8.130Open8.110Pre Close1.22MTurnover0.56%Turnover RatioLossP/E (Static)44.79MShares20.90052wk High3.95P/B220.66MFloat Cap6.48052wk Low--Dividend TTM27.07MShs Float55.215Historical High--Div YieldTTM5.24%Amplitude2.700Historical Low8.107Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Shareholders in Y-mAbs Therapeutics (NASDAQ:YMAB) Have Lost 74%, as Stock Drops 14% This Past Week
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash Wisely
Clear Street Launches Healthcare & Biotechnology Equity Research
JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23
Promising Preclinical Data on CD38-SADA Justifies Buy Rating for Y-Mabs Therapeutics
Heat List
US
Overall
Symbol
Price
% Chg
No Data